# [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma

> **NCT07655869** · EARLY_PHASE1 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent High-Grade Gliomas
- Recurrent Glioblastoma IDH Wildtype

## Interventions

- **DRUG:** [177Lu]Lu-DOTA-EB-RGD2

## Key facts

- **NCT ID:** NCT07655869
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07655869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07655869, "[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07655869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*